Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection

Background: Telaprevir in combination with peginterferon and ribavirin is a promising advancement in chronic hepatitis C treatment. However, the safety, tolerability, pharmacokinetics and antiviral profiles of telaprevir alone beyond 2 weeks have not been studied. Methods: In a phase 1b study in Jap...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, I, Suzuki, F, Kamiya, N, Aoki, K, Sakurai, Y, Kano, M, Matsui, H, Kumada, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2012
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584515/
https://www.ncbi.nlm.nih.gov/pubmed/22239508
http://dx.doi.org/10.1111/j.1365-2893.2011.01514.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584515/
https://www.ncbi.nlm.nih.gov/pubmed/22239508
http://dx.doi.org/10.1111/j.1365-2893.2011.01514.x

Ejemplares similares